Skip to main content

RT @RichardPAConway: Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safe

Nov 14, 2022 7:09 am
Social Author Name
Richard Conway
Tweet Content
Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×